Biogen resumed with a Market Perform at Raymond James. Raymond James analyst Steven Seedhouse resumed coverage of Biogen with a Market Perform rating, stating that the company’s remaining business following the failure of aducanumab “appears a little fragile” and faces “existential risk” in some cases, such as the Tecfidera IPR decision due in 2020. Near-term pipeline readouts, including the nearest readouts on Vumerity and BIIB067, don’t seem high-impact enough to reverse sentiment, Seedhouse tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.